TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18278978

Group type: EXPERIMENTAL
Intervention: bupropion SR 150 mg/day
Number of subjects: 1524

Group type: EXPERIMENTAL
Intervention: bupropion SR 300 mg/day
Number of subjects: 1524
Study: 17099376

Group type: EXPERIMENTAL
Intervention: Intravenous cefuroxime 750 mg just before the procedure followed by two further doses every 8 h (Group A)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Single application of povidone-iodine (Betadine) antiseptic spray (Group B)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combination of cefuroxime and Betadine spray (Group C)
Number of subjects: 96
Study: 12958051

Group type: EXPERIMENTAL
Intervention: Noninvasive pressure support ventilation
Number of subjects: 130

Group type: COMPARATOR
Intervention: Medical therapy plus O2
Number of subjects: 130
Study: 11189691

Group type: EXPERIMENTAL
Intervention: Death review process in the PLCO Cancer Screening Trial
Number of subjects: 0
Study: 9308557

Group type: EXPERIMENTAL
Intervention: Prilocaine-lidocaine patch (anesthetic patch)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 60
Study: 8346498

Group type: EXPERIMENTAL
Intervention: Nicotine (0.08‐2.0 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nicotine (2.0 mg given eight times daily for nine days)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Histamine challenge after acute doses of nicotine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Histamine challenge during prolonged treatment with nicotine
Number of subjects: 20
Study: 2940370

Group type: EXPERIMENTAL
Intervention: Behavioral treatment methods (B regimen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional management (A regimen)
Number of subjects: 0
Study: 30089655

Group type: EXPERIMENTAL
Intervention: Lifestyle advice (n = 816)
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Standard care (n = 786)
Number of subjects: 1602

Group type: EXPERIMENTAL
Intervention: Lifestyle advice
Number of subjects: 1602

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1602
Study: 26809850

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188

Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 188

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 188
Study: 25313098

Group type: EXPERIMENTAL
Intervention: Mating motive prime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control prime
Number of subjects: 0
Study: 23913968

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 48

Group type: COMPARATOR
Intervention: Basiliximab/low-dose rabbit anti-thymocyte globulin (Bas/rATG)
Number of subjects: 48
Study: 21429514

Group type: EXPERIMENTAL
Intervention: Protein-enriched diet (1.1 g protein/100 mL of feeding formula)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Protein-enriched diet
Number of subjects: 51
Study: 18344756

Group type: EXPERIMENTAL
Intervention: Semiautomated kinetic perimetry (SKP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Goldmann manual kinetic perimetry (GVF)
Number of subjects: 10
Study: 17006921

Group type: EXPERIMENTAL
Intervention: Clonidine (0.075 mg) twice daily for 3 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 12687864

Group type: EXPERIMENTAL
Intervention: DDDR pacing driven by contractility
Number of subjects: 23

Group type: COMPARATOR
Intervention: DDI pacing
Number of subjects: 23
Study: 11110232

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 141

Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 141
Study: 8649238

Group type: EXPERIMENTAL
Intervention: Human milk (breast-fed)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Formula without AA and DHA (unsupplemented)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Formula with AA and DHA (supplemented)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Formula with corn oil (for neonates with phenylketonuria)
Number of subjects: 20
Study: 1545089

Group type: EXPERIMENTAL
Intervention: Inhaled gallopamil (20 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 3944721

Group type: EXPERIMENTAL
Intervention: Semi-sitting position with male physician
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Supine position with female physician
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Semi-sitting position with male physician (previous pelvic examination)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Semi-sitting position with female physician (never had pelvic examination)
Number of subjects: 112
Study: 29373513

Group type: COMPARATOR
Intervention: 1.5 servings/day of chopped almonds
Number of subjects: 18

Group type: COMPARATOR
Intervention: 1.5 servings/day of whole almonds
Number of subjects: 18

Group type: COMPARATOR
Intervention: 1.5 servings/day of almond butter
Number of subjects: 18
Study: 26795716

Group type: EXPERIMENTAL
Intervention: Visual biofeedback group (8 individuals)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nonbiofeedback group (10 individuals)
Number of subjects: 18
Study: 24342688

Group type: EXPERIMENTAL
Intervention: 40% steam‐flaked brown rice (BR)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 40% steam‐flaked corn
Number of subjects: 9
Study: 21521379

Group type: EXPERIMENTAL
Intervention: Topical triiodothyronine ointment applied twice daily for 12 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo applied twice daily for 12 weeks
Number of subjects: 10
Study: 15965585

Group type: EXPERIMENTAL
Intervention: Arm BASIS training
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Arm BASIS training with APB representation at pre test
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control conditions (non‐intensified vs. intensified therapy, Bobath approach)
Number of subjects: 28
Study: 11809594

Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg/day
Number of subjects: 1553

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1553
Study: 9673554

Group type: EXPERIMENTAL
Intervention: Normal saline 25 to 30 ml/kg body weight at 37 degrees C infused under the right hemidiaphragm (Group C)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Normal saline at room temperature infused under the right hemidiaphragm and suctioned after deflation (Group D)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Normal saline infused and suctioned as in Group D, but with a subhepatic closed drain left for 24 hours (Group E)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No peritoneal infusion, no subhepatic drain (Group A)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No peritoneal infusion but a subhepatic closed drain left for 24 hours (Group B)
Number of subjects: 300
Study: 8079849

Group type: EXPERIMENTAL
Intervention: 125 ml of iohexol 350
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: 150 ml of iohexol 300
Number of subjects: 902

Group type: COMPARATOR
Intervention: 150 ml of diatrizoate meglumine 60%
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: iohexol 240
Number of subjects: 902
Study: 2642435

Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1017281

Group type: EXPERIMENTAL
Intervention: New tar gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crude coal tar
Number of subjects: 0
Study: 31390293

Group type: EXPERIMENTAL
Intervention: ECHO‐delivered palliative care education program (10 interactive sessions over five months)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: ECHO‐delivered palliative care education program
Number of subjects: 353
Study: 30075763

Group type: EXPERIMENTAL
Intervention: Cytosponge-TFF3 test
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study: 26649555

Group type: EXPERIMENTAL
Intervention: PLIF
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: TLIF
Number of subjects: 66
Study: 24906374

Group type: EXPERIMENTAL
Intervention: Active tDCS (n = 7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham tDCS (n = 7)
Number of subjects: 14
Study: 22327131

Group type: EXPERIMENTAL
Intervention: Palifermin 60 μg/kg daily for three consecutive days before conditioning and a single dose of 180 μg/kg after conditioning.
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Palifermin
Number of subjects: 155
Study: 20337955

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propofol-ketamine combination
Number of subjects: 40
Study: 18380946

Group type: EXPERIMENTAL
Intervention: OROS hydromorphone
Number of subjects: 127
Study: 16128481

Group type: EXPERIMENTAL
Intervention: Health-related fitness school-based program and home program with parent involvement
Number of subjects: 238

Group type: COMPARATOR
Intervention: Traditional physical education and nutrition education program
Number of subjects: 238
Study: 11860649

Group type: EXPERIMENTAL
Intervention: Topical bupivacaine
Number of subjects: 99

Group type: COMPARATOR
Intervention: Saline-soaked swabs (Control)
Number of subjects: 99
Study: 10449850

Group type: EXPERIMENTAL
Intervention: Repair with polytetrafluoroethylene (PTFE)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Repair without polytetrafluoroethylene (PTFE)
Number of subjects: 35
Study: 7887701

Group type: EXPERIMENTAL
Intervention: Narrow-spectrum (nafcillin)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Midspectrum (cephapirin)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Broad-spectrum (ceftriaxone)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 78
Study: 2297305

Group type: EXPERIMENTAL
Intervention: Botulinum A toxin
Number of subjects: 5

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 5
Study: 358366

Group type: EXPERIMENTAL
Intervention: Early surgery (ES), operated within 7 days after the onset of acute symptoms
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed surgery (DS), operated 2-3 months after the acute episode
Number of subjects: 100
Study: 31498447

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA)
Number of subjects: 30207

Group type: EXPERIMENTAL
Intervention: No therapy
Number of subjects: 30207

Group type: EXPERIMENTAL
Intervention: Patients with RA-DNI
Number of subjects: 30207

Group type: COMPARATOR
Intervention: Patients without RA
Number of subjects: 30207
Study: 31256082

Group type: EXPERIMENTAL
Intervention: Aquatic motor dual task training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Land motor dual task training
Number of subjects: 50
Study: 28735851

Group type: COMPARATOR
Intervention: Added fiber (AF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No added fiber (NF)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Whole black beans (BN)
Number of subjects: 12
Study: 26039688

Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Citalopram 40 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23564564

Group type: EXPERIMENTAL
Intervention: Peg‐IFN group (31 patients received Peg‐IFN subcutaneously at a dose of 50 μg per week for 12 months)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (62 patients followed only, no adjuvant therapies)
Number of subjects: 93
Study: 22055259

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 1791

Group type: COMPARATOR
Intervention: Control (standard glucose control)
Number of subjects: 1791
Study: 19393000

Group type: EXPERIMENTAL
Intervention: Xolair (anti-IgE treatment) for 16 weeks in patients with high IgE fraction (>3.8%)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Xolair (anti-IgE treatment) for 16 weeks in patients with low IgE fraction (<1%)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo for 16 weeks in patients with high IgE fraction (>3.8%)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo for 16 weeks in patients with low IgE fraction (<1%)
Number of subjects: 38
Study: 16393304

Group type: EXPERIMENTAL
Intervention: L. rhamnosus strains (573L/1; 573L/2; 573L/3) administered at a dose of 1.2 x 10(10) CFU, twice daily, for 5 days
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: L. rhamnosus strains (573L/1; 573L/2; 573L/3) in rotavirus infection
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo in rotavirus infection
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: L. rhamnosus strains (573L/1; 573L/2; 573L/3)
Number of subjects: 87
Study: 15316913

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 11357896

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg IV
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg orally
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 9393527

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine-enhanced MR imaging
Number of subjects: 28
Study: 7949622

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at a dose of 0.7 IU/kg/week (group B)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at a dose of 1.4 IU/kg/week (group C)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 130
Study: 2897559

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g once daily)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Gentamicin plus cefuroxime (combination therapy)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 105

Group type: COMPARATOR
Intervention: Gentamicin plus cefuroxime
Number of subjects: 105
Study: 27536927

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Church leader support and strength of parishioners' connection to the church
Number of subjects: 0
Study: 24356320

Group type: EXPERIMENTAL
Intervention: Bayley-III Low Motor/Vision accommodated version
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard Bayley-III
Number of subjects: 19
Study: 23704089

Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (L-DNR)
Number of subjects: 521

Group type: COMPARATOR
Intervention: Idarubicin
Number of subjects: 521
Study: 20940718

Group type: EXPERIMENTAL
Intervention: FOLFOX4 (6 cycles: 3 concomitant and 3 post-radiotherapy)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Cisplatin/fluorouracil (4 cycles: 2 concomitant and 2 post-radiotherapy)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: FOLFOX4
Number of subjects: 97

Group type: COMPARATOR
Intervention: Cisplatin/fluorouracil
Number of subjects: 97
Study: 17940996

Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity measures in treatment groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proportional hazards model for time-to-event outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prentice criterion
Number of subjects: 0
Study: 16816151

Group type: EXPERIMENTAL
Intervention: Neurocognitive testing (Immediate Postconcussion Assessment and Cognitive Testing)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurocognitive testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neurocognitive testing and symptom assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (noninjured athletes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symptom and neurocognitive test results
Number of subjects: 0
Study: 12504932

Group type: EXPERIMENTAL
Intervention: Immediate delivery
Number of subjects: 548

Group type: COMPARATOR
Intervention: Delay until the obstetrician is no longer uncertain
Number of subjects: 548
Study: 10378821

Group type: EXPERIMENTAL
Intervention: Triflusal (600 mg/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) (300 mg/day)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Triflusal
Number of subjects: 43

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 43
Study: 8906524

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 1632

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1632
Study: 1864770

Group type: EXPERIMENTAL
Intervention: Resistance training program (12 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no active intervention)
Number of subjects: 27
Study: 6638451

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthetic technique of fentanyl and methohexitone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl, methohexitone, nitrous oxide and trichloroethylene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving no general anaesthesia
Number of subjects: 0
Study: 30618285

Group type: EXPERIMENTAL
Intervention: Theta Burst Stimulation (TBS) + Physical Therapy (PT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) + Physical Therapy (PT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physical Therapy (PT) alone
Number of subjects: 60
Study: 30005654

Group type: EXPERIMENTAL
Intervention: Combined resistance exercise training guided by a physiotherapist twice a week and increased protein intake under the supervision of a dietitian
Number of subjects: 200

Group type: COMPARATOR
Intervention: Regular care
Number of subjects: 200
Study: 27502760

Group type: EXPERIMENTAL
Intervention: Conceptual instruction (two iterations)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Combined conceptual and procedural instruction
Number of subjects: 180
Study: 24158305

Group type: EXPERIMENTAL
Intervention: Simulated patient death
Number of subjects: 116

Group type: COMPARATOR
Intervention: Simulated patient transferred to another service
Number of subjects: 116
Study: 25058962

Group type: EXPERIMENTAL
Intervention: Suspine rotation manipulation
Number of subjects: 134

Group type: COMPARATOR
Intervention: Flexion manipulation
Number of subjects: 134
Study: 19114175

Group type: EXPERIMENTAL
Intervention: IMVAMUNE (Modified Vaccinia Ankara vaccine) followed by Dryvax
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cardiologist over-read of computer-generated ECG statements
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Echocardiograms performed in subjects with abnormal ECG findings
Number of subjects: 90
Study: 17686255

Group type: EXPERIMENTAL
Intervention: Extended-release metformin 1500 mg qd for 12 weeks
Number of subjects: 150

Group type: COMPARATOR
Intervention: Glucophage (metformin, 500 mg, tid) for 12 weeks
Number of subjects: 150
Study: 15086935

Group type: EXPERIMENTAL
Intervention: Calcium Acetate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sevelamer Hydrochloride
Number of subjects: 100
Study: 11333795

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 96
Study: 9732190

Group type: EXPERIMENTAL
Intervention: TUVP
Number of subjects: 104

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 104
Study: 8054125

Group type: EXPERIMENTAL
Intervention: Early ambulation (6 hours of bedrest post sheath removal)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard care (8 hours of bedrest post sheath removal)
Number of subjects: 85
Study: 2903219

Group type: EXPERIMENTAL
Intervention: Preexposure condition (30 bursts of white noise while monitoring nonsense syllables)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Non-preexposure condition (listening to nonsense syllables without white noise)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Retesting after 6 to 7 weeks for both acute and chronic patients
Number of subjects: 106
Study: 1586711

Group type: EXPERIMENTAL
Intervention: rhIL-3/rhGM-CSF
Number of subjects: 15

Group type: COMPARATOR
Intervention: rhIL-3
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-dose rhIL-3
Number of subjects: 15
Study: 363047

Group type: EXPERIMENTAL
Intervention: Carbenicillin administered intravenously
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbenicillin administered intramuscularly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbenicillin (general use)
Number of subjects: 0
Study: 31378010

Group type: EXPERIMENTAL
Intervention: Facial emotional cue of anger
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Facial emotional cue of sadness
Number of subjects: 251

Group type: COMPARATOR
Intervention: Facial emotional cue of neutral expression
Number of subjects: 251

Group type: COMPARATOR
Intervention: Absence of facial expression
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Overall aggression levels across conditions for men
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Overall aggression levels across conditions for women
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Instrumental motives
Number of subjects: 251
Study: 28319997

Group type: EXPERIMENTAL
Intervention: Single glucocorticoid intradiscal injection (25 mg prednisolone acetate)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Discography alone (control group)
Number of subjects: 135
Study: 26510577

Group type: EXPERIMENTAL
Intervention: Practice facilitation (intensive visits every 3-4 weeks in year 1, 6-12 weeks in year 2)
Number of subjects: 5292

Group type: EXPERIMENTAL
Intervention: Practice facilitation (sustainability visits every 6-12 weeks in year 2)
Number of subjects: 5292
Study: 23452107

Group type: EXPERIMENTAL
Intervention: Heavy smoking (more than one pack of cigarettes per day)
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Smoking the first cigarette of the day within 30 min of waking
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Smoking initiation at earlier age
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Higher temptation to smoke
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Household smoking or living alone
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Exposure to chemicals at work
Number of subjects: 763
Study: 21481514

Group type: EXPERIMENTAL
Intervention: ESS-EMNCH training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (untrained)
Number of subjects: 36
Study: 19453643

Group type: EXPERIMENTAL
Intervention: Heart transplant recipients
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Liver transplant recipients
Number of subjects: 69